NGM Biopharmaceuticals, Inc. 0IK.F Stock
NGM Biopharmaceuticals, Inc. Price Chart
NGM Biopharmaceuticals, Inc. 0IK.F Financial and Trading Overview
NGM Biopharmaceuticals, Inc. stock price | 1.41 EUR |
Previous Close | 3.16 EUR |
Open | 3.18 EUR |
Bid | 3.18 EUR x 0 |
Ask | 3.28 EUR x 0 |
Day's Range | 3.18 - 3.18 EUR |
52 Week Range | 2.74 - 17.1 EUR |
Volume | 778 EUR |
Avg. Volume | 13 EUR |
Market Cap | 261.9M EUR |
Beta (5Y Monthly) | 1.213975 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 34.83 EUR |
0IK.F Valuation Measures
Enterprise Value | 41.56M EUR |
Trailing P/E | N/A |
Forward P/E | -1.5979899 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 7.1495223 |
Price/Book (mrq) | 1.1812779 |
Enterprise Value/Revenue | 1.135 |
Enterprise Value/EBITDA | -0.23 |
Trading Information
NGM Biopharmaceuticals, Inc. Stock Price History
Beta (5Y Monthly) | 1.213975 |
52-Week Change | -73.057% |
S&P500 52-Week Change | 20.43% |
52 Week High | 17.1 EUR |
52 Week Low | 2.74 EUR |
50-Day Moving Average | 3.36 EUR |
200-Day Moving Average | 5.96 EUR |
0IK.F Share Statistics
Avg. Volume (3 month) | 13 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 82.36M |
Float | 39.99M |
Short Ratio | N/A |
% Held by Insiders | 21.77% |
% Held by Institutions | 61.87% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -501.91% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -37.15% |
Return on Equity (ttm) | -66.85% |
Income Statement
Revenue (ttm) | 36.63M EUR |
Revenue Per Share (ttm) | 0.45 EUR |
Quarterly Revenue Growth (yoy) | -89.29% |
Gross Profit (ttm) | -125734000 EUR |
EBITDA | -180644992 EUR |
Net Income Avi to Common (ttm) | -177864000 EUR |
Diluted EPS (ttm) | -2.11 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 231M EUR |
Total Cash Per Share (mrq) | 2.81 EUR |
Total Debt (mrq) | 4.07M EUR |
Total Debt/Equity (mrq) | 1.84 EUR |
Current Ratio (mrq) | 6.399 |
Book Value Per Share (mrq) | 2.692 |
Cash Flow Statement
Operating Cash Flow (ttm) | -150528000 EUR |
Levered Free Cash Flow (ttm) | -90154752 EUR |
Profile of NGM Biopharmaceuticals, Inc.
Country | Germany |
State | CA |
City | South San Francisco |
Address | 333 Oyster Point Boulevard |
ZIP | 94080 |
Phone | 650 243 5555 |
Website | https://www.ngmbio.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 239 |
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
Q&A For NGM Biopharmaceuticals, Inc. Stock
What is a current 0IK.F stock price?
NGM Biopharmaceuticals, Inc. 0IK.F stock price today per share is 1.41 EUR.
How to purchase NGM Biopharmaceuticals, Inc. stock?
You can buy 0IK.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for NGM Biopharmaceuticals, Inc.?
The stock symbol or ticker of NGM Biopharmaceuticals, Inc. is 0IK.F.
Which industry does the NGM Biopharmaceuticals, Inc. company belong to?
The NGM Biopharmaceuticals, Inc. industry is Biotechnology.
How many shares does NGM Biopharmaceuticals, Inc. have in circulation?
The max supply of NGM Biopharmaceuticals, Inc. shares is 87.91M.
What is NGM Biopharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?
NGM Biopharmaceuticals, Inc. PE Ratio is 0.00000000 now.
What was NGM Biopharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?
NGM Biopharmaceuticals, Inc. EPS is 0 EUR over the trailing 12 months.
Which sector does the NGM Biopharmaceuticals, Inc. company belong to?
The NGM Biopharmaceuticals, Inc. sector is Healthcare.